Toujeo® Doublestar and Solostar Prefilled Insulin Pens for Basal Control

What Toujeo® Is and How It Works

Toujeo is insulin glargine U‑300, a long‑acting basal insulin for type 1 and type 2 diabetes. It delivers a steady effect over 24 hours or longer with once‑daily dosing. The Toujeo Doublestar/Solostar Prefilled Pen provides concentrated insulin in compact pens designed for reliable basal coverage. Some patients look for Toujeo Doublestar/Solostar without insurance options to manage out‑of‑pocket costs.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies.

We work with vetted partner pharmacies to supply authentic brand medications at value‑focused pricing and a broad selection.

Toujeo SoloStar is a 300 units/mL prefilled pen with 1‑unit dosing steps and up to 80 units per injection (1.5 mL pen; 450 units total). Toujeo DoubleStar is a higher‑capacity 300 units/mL pen with 2‑unit dosing steps and up to 160 units per injection (3 mL pen; 900 units total). Both are for subcutaneous injection only and are not for pumps, intravenous use, or mixing with other insulins.

Indications vary by region, but Toujeo is commonly used in adults and certain pediatric patients to improve glycemic control. It is not for diabetic ketoacidosis (DKA). Dose adjustments are individualized and guided by fasting glucose trends and overall therapy goals.

Dosage and Usage

• Use once daily at the same time each day. A consistent schedule supports stable fasting glucose.
• Initiation and titration follow clinical direction. Dose changes often occur every few days based on glucose logs.
• Pen choice: SoloStar allows 1‑unit steps (max 80 units/injection). DoubleStar allows 2‑unit steps (even numbers only; max 160 units/injection).
• Prime the pen per the Instructions for Use until a drop appears before the first dose and after needle changes.
• Inject into the abdomen, thigh, or upper arm. Rotate sites to reduce lipodystrophy.
• Do not administer intravenously or in an insulin pump. Do not mix with other insulins.
• Missed dose: take during the same day when remembered. Do not take more than one dose in 24 hours.
• Conversion from other basal insulins needs clinical oversight. Some patients may require dose changes when switching.
• Never share pens or needles.

• Store unused pens in a refrigerator at 2–8°C (36–46°F). Do not freeze. Keep in the carton to protect from light.
• In use, keep pens at room temperature below 30°C (86°F) for up to 6 weeks (42 days). Do not refrigerate after first use.
• Keep pens away from heat and direct sunlight. Discard after the in‑use period even if insulin remains.
• Travel: carry pens and supplies in hand luggage with a cool pack. Avoid freezing. Keep an extra pen and needles.
• Use a sharps container for used needles. Carry medical identification when traveling.

Benefits and Savings

Toujeo’s U‑300 formulation provides a flat, prolonged action profile that helps reduce glucose variability, including overnight. Concentrated insulin means smaller injection volumes at higher doses, which may improve comfort. DoubleStar’s higher maximum per injection can reduce multiple injections for those needing larger basal doses.

Once‑daily dosing simplifies routines, and pen devices are discreet and portable. Many customers save 60–80% vs typical U.S. prices. For those comparing Toujeo Doublestar price without insurance, cross‑border pricing can help lower out‑of‑pocket spend.

See our promotions page for current offers, including any Toujeo Doublestar/Solostar Pen coupon if available.

Side Effects and Safety

• Hypoglycemia (shakiness, sweating, hunger, headache)
• Injection‑site reactions (redness, itching)
• Weight gain and peripheral edema
• Lipodystrophy or skin thickening at injection sites
• Allergic reactions (rash)
• Itching or mild local discomfort

Serious risks include severe hypoglycemia, hypokalemia, and rare systemic allergic reactions. Fluid retention may worsen with thiazolidinediones (e.g., pioglitazone). Do not use during episodes of diabetic ketoacidosis. The risk of hypoglycemia increases when used with prandial insulin or sulfonylureas; background doses may need adjustment under clinical guidance.

Onset Time

Toujeo starts working gradually after injection and builds a steady effect with daily use. Many patients see fasting glucose improvements within the first week as titration begins. Full steady state often takes 3–4 days after a dose change, and A1C changes are typically assessed over 8–12 weeks.

Because Toujeo has a flatter profile and less pronounced peak than many U‑100 basal insulins, it supports stable overnight control. Individual responses vary based on dose, timing, injection technique, and concurrent medications.

Compare With Alternatives

Several basal insulins are used for long‑acting coverage. Lantus (insulin glargine U‑100) and biosimilar glargine products offer once‑daily dosing but are less concentrated than Toujeo U‑300. Patients switching from U‑100 to U‑300 may need a higher unit dose due to pharmacokinetic differences.

Tresiba (insulin degludec U‑100/U‑200) is an ultra‑long‑acting option with flexible dosing windows. Levemir (insulin detemir) may require once‑ or twice‑daily dosing depending on needs. Choice depends on dosing flexibility, injection volume, cost, and clinical response. For background on insulin selection and titration, see Insulin Dosage Chart How Much Insulin Do You Need. For broader metabolic considerations, review Insulin And Weight Gain What Patients Should Know.

Combination Therapy

• Metformin plus Toujeo is common in type 2 diabetes.
• GLP‑1 receptor agonists may be combined with basal insulin to improve glycemia and weight profile.
• SGLT2 inhibitors can be added for cardiovascular and renal benefits in appropriate patients.
• Prandial insulin may be added for mealtime control; example: Humulin R 100u Ml 10ml vial for syringe use.
• When adding or intensifying prandial insulin or sulfonylureas, consider reducing doses to lower hypoglycemia risk.
• Review dose algorithms and targets with a clinician; see Insulin Dosage Chart How Much Insulin Do You Need for general frameworks.

Patient Suitability and Cost‑Saving Tips

Toujeo may suit adults and certain pediatric patients who need long‑acting basal insulin with a stable profile. DoubleStar can be helpful for higher daily requirements that exceed SoloStar’s per‑injection maximum. It is not appropriate for DKA, insulin pump use, or those needing rapid correction of acute hyperglycemia.

Caution is advised in people with recurrent severe hypoglycemia, hypokalemia, or significant renal or hepatic impairment. Pen devices require the ability to perform subcutaneous injections reliably and rotate sites. For condition‑specific guidance, visit Type 1 Diabetes and Type 2 Diabetes.

Cost‑saving ideas include choosing multi‑month quantities, consolidating shipments, and selecting DoubleStar when appropriate to reduce the number of pens needed at higher doses. Set simple reminders for reordering before pens expire or run low. CanadianInsulin ships with prompt, express, cold‑chain handling to maintain medication integrity.

Authoritative Sources

Toujeo (insulin glargine) U‑300 — Sanofi Product Information

Health Canada Product Monograph — Toujeo

FDA Prescribing Information — Toujeo

Order Toujeo® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and is not a substitute for professional medical advice. Discuss individual dosing, switching, and safety with a licensed healthcare provider.